Home > Insider Trading > Filing (0001104659-19-041306)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1680581	Fulcrum Therapeutics Inc.	FULC	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1534260	Casdin Partners Gp, Llc	1350 Avenue Of The Americas Suite 2600 New York NY 10019	No	No	Yes	No
1534261	Casdin Capital, Llc	1350 Avenue Of The Americas Suite 2600 New York NY 10019	No	No	Yes	No
1534264	Eli Casdin	1350 Avenue Of The Americas Suite 2600 New York NY 10019	No	No	Yes	No
1534265	Casdin Partners Master Fund, L.p.	1350 Avenue Of The Americas Suite 2600 New York NY 10019	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-07-22	464,285	$0.00	464,285	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2019-07-22	125,000	$16.00	589,285	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2019-07-22	10,000	$14.50	599,285	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2019-07-22	5,000	$14.50	604,285	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2019-07-22	3,250,000	$0.00	464,285	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.